FDA Approves CRISPR-based Therapeutic for TrialAugust 24, 2022
Cure Rare Disease, a Boston-based nonprofit organization developing genetic medicines, has received approval from the Food and Drug Administration (FDA) to administer its CRISPR-based therapeutic that halts the progression of Duchenne muscular dystrophy.
Duchenne muscular dystrophy is a rare genetic disease caused by a mutation in the gene responsible for dystrophin production. It can affect all muscle types and leads to loss of mobility and eventually to respiratory and cardiac failure. The disease impacts 1 in 3,500 males and is extremely rare in females.
The drug, CRD-TMH-001, treats muscle promoter and exon 1 mutations on the dystrophin gene. With the FDA approval, dosing of the drug will take place at the University of Massachusetts Medical School very soon.
The therapeutic has been developed for one-time administration. It will be administered intravenously, and the patient will be under observation in the hospital for several days to ensure that there are no uncontrolled adverse reactions. As per FDA guidelines, the patient's progress will be tracked for 15 years.Read more from Cure Rare Disease.
You might also like:
- Experts Modify RNA Guides for CRISPR Tools and Therapies
- Experts Broaden Target Range of CRISPR-Cas Systems
- Pocket K No. 54: Plant Breeding Innovation: CRISPR-Cas9
The Crop Biotech Update is a weekly newsletter of ISAAA, a not-for-profit organization. The CBU is distributed for free to over 23,000 subscribers worldwide to inform them about the key developments in biosciences, especially in agricultural biotechnology. Your support will help us in our mission to feed the world with knowledge. You can help by donating as little as $10.
See more articles:
Research and Tools
- Enhanced Green Fluorescent Marker Effective in Transforming Grapes Using CRISPR
- UC San Diego Researchers Use CRISPR to Target Global Crop Pest
- CRISPR Method Successfully Developed for Medicinal Fungus
- CRISPR-Based Test Enables Fast and Accurate Detection of SARS-CoV-2 Variants
- FDA Approves CRISPR-based Therapeutic for Trial
Trends and Impact
- CRISPR Market Size to Reach US$3.73B by 2032
Read the latest:
- Crop Biotech Update (January 25, 2023)
- Genome Editing Supplement (January 18, 2023)
- Gene Drive Supplement (January 25, 2023)
Subscribe to CBU: